



## **5<sup>th</sup> OKIDS Congress**

### **Access to Innovation and Cross Border Health Care for Children and Adolescents:**

### **Regional – National – International**

**25.06.2026**

**Apothekertrakt Schloss Schönbrunn**

**Prefinal PROGRAMME**



## Pre Final PROGRAMM

**OKIDS** GmbH was founded in 2012 as a subsidiary of the ÖGKJ (Austrian Society for Paediatrics and Adolescent Medicine, [www.paediatric.at](http://www.paediatric.at)) and was based on the model of public-private partnership: in the founding phase the Austrian Federal Ministry of Health (BMG), and in the start-up phase until today via partnerships or funding by Pharmig and the industry, the Joint Health Targets from the Pharma Master Agreement, the „Österreichische Gesundheitskasse“ and the Austrian Society for Paediatrics and Adolescent Medicine (ÖGKJ).



**OKIDS** is a non-profit company with a network of renowned paediatric centres throughout Austria aiming at improving medicinal product safety and efficacy in children and adolescents by means of clinical studies.

### Funding Support



### Supporting Companies 2024-2026



Registration open till June 23th, 2026. Congress admittance free of charge.

# Pre Final PROGRAMM

8:30 – 9:00 WELCOME COFFEE

9:00

## OPENING ADDRESS

- **Prim. Univ.-Prof. Dr. Reinhold Kerbl**  
General Secretary of the Austrian Society of Paediatrics and Adolescent Medicine (ÖGKJ)
- **OKIDS – The AUSTRIAN Medicines for Children Network 2026**  
Prof. Dr. Ruth Ladenstein, OKIDS GmbH, Vienna

## 9: 30 SESSION 1: CLINICAL TRIALS & REGISTRIES

- **Recent developments in the Paediatric Trial Landscape in Europe: Innovative designs and regulators (EMA) perspectives.**  
Prof. Mark Turner, Chief Executive Officer conect4children Stichting
- **Role of Registries and Observational Studies in view of EHDS & Austrian Experiences with the CTIS implementation**
  - **The Austrian KKS Perspectives**  
Mag. Sabine Embacher- Aichhorn, KKS- Medizinische Universität Innsbruck
  - **The Austrian Lead Ethical Committee Perspectives**  
Prof. Martin Brunner, Medical University Vienna
- **Digital Health Information Systems for Big Data: Roles for Registries, Telehealth and mHealth and Artificial Intelligence**  
DI Dr. Dieter Hayn, MBA  
Senior Scientist, Center for Health & Bioresources  
AIT Austrian Institute of Technology GmbH
- **Austria's successful SUPA Implementation in ELGA and the SUPA Registry (10' +5)**  
DI (FH) Angelika Rzepka, MPHAngelika Rzepka  
Senior Research Engineer, Digital Health Information Systems  
Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH

10:45 COFFEE BREAK

- **NEWS from ELGA – Getting ready for EHDS**  
Dr. Stefan Sabutsch, Director, ELGA GmbH
- **Paediatric Cancer Data from the Austrian National Cancer Registry – Methods and Access Requirements in view of EHDS**  
Mag. Dr.scient.med. Monika Hackl, BUNDESANSTALT STATISTIK ÖSTERREICH  
Direktion Bevölkerung, Gesundheitsstatistik

## 11:30 SESSION 2: Legislation & EHDS

## Pre Final PROGRAMM

- **Spectrum of the Recent European Legislation: Key Impacts on Health & R&D**  
Prof. N. Forgo, University of Vienna
- **European Reference Networks in Action: The Declaration for Rare Diseases and the Health Biotech Act: Innovation Opportunities for Europe**  
Prof. Dr. Ruth Ladenstein, ERN PaedCan Coordinator and ERN Chair
- **Industry perspectives on the EU BIOTECH ACT**  
Dr. Holzhauser, PHARMIG
- **FAST-EU – First experiences with the assessment model proposed by the EU Biotech Act.**  
Dr. Stefan Strasser, Head of Department, Department Clinical Trials  
Institute Surveillance, Austrian Medicines and Medical Devices Agency  
BASG - Federal Office for Safety in Health Care

### 12:45- 13:30 ROUNDTABLE

#### **Future Role of Registries in view of EHDS: Are we fit for purpose?**

Prof. Mark Turner, Prof. Martin Brunner, DI Dr. Dieter Hayn, Prof. N. Forgo, Dr. Stefan Strasser, Mag. Dr.scient.med. Monika Hackl

### LUNCH BREAK & Coffee 13:30 -14:30

### 14:30 SESSION 3: Innovations in Clinical Trials for Young People in Austria - OKIDS Sites

- **Chimeric Antigen Receptor (CAR) T-cells in relapsed and refractory paediatric ALL – an alternative to immunotherapy and allogeneic HSCT**  
*Univ. Prof. Dr. Andishe Attarbashi, St. Anna Children's Hospital (Co-Director) & Childrens Cancer Research Institute, Head of CTU, Vienna Austria*
- **New therapeutic strategies in monogenetic and syndromic obesity in childhood.**  
*Univ. Prof. Dr. Susanne Greber-Platzer, MBA, Division of Pediatric Pulmonology, Allergology and Endocrinology, Head of Department of Paediatrics and Adolescent Medicine, Medical University of Vienna*
- **The spectrum of disease in Hypophosphatasia: Lessons learnt by the ALPL VCEP**  
*Univ. Prof. Dr. Wolfgang Högl, Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz*
- **Targeted Therapy for Vascular Anomalies: Young Hope Research at the National Centre**  
*Dr. Ulrike Metzger, University Hospital for Paediatrics and Adolescent Medicine of Paracelsus Medical Private University and Clinical Research Centre Salzburg GmbH*
- **Listening to Children in Clinical Trials: From PROMs to Actionable Symptom Interventions.**  
*Univ.-Prof. Mag. Dr. Roman Crazzolara, Department of Paediatrics I  
Medical University of Innsbruck*

## Pre Final PROGRAMM

- **Dinutuximab beta long term infusion is associated with a survival advantage over short term infusion in patients with high-risk neuroblastoma. Results from the HR-NBL1/SIOPEN trial.**

*Prof. Dr. Ruth Ladenstein, MBA, St. Anna Children's Hospital & Childrens Cancer Research Institute, Vienna Austria*

**FARWELL NETWORKING (DRINKS & SNACKS)**

**16:00 – 17:00**